A research team led by Prof. YUAN Shuguang from the Shenzhen Institutes of Advanced Technology has confirmed that clinical histone deacetylase (HDAC) inhibitors can efficiently prevent SARS-CoV-2 and potentially be used to fight against COVID-19.
The COVID-19 pandemic has highlighted the need for rapid and accurate nucleic acid detection at the point of care. To meet this need, scientists from the Suzhou Institute of Biomedical Engineering and Technology have developed a novel amplification-free rapid SARS-CoV-2 nucleic acid detection platform based on hybrid capture fluorescence immunoassay (HC-FIA).
Researchers from the Shenzhen Institutes of Advanced Technology and their collaborators found that lung distribution of antivirals drugs affects their performance in COVID-19 treatment.
SARS-CoV-2 can infect human neural progenitor cells and brain organoids, as shown by researchers from the Shenzhen Institutes of Advanced Technology and their collaborators from The University of Hong Kong.
On June 5, 2020, China's National Medical Products Administration (NMPA) officially approved the clinical trials for a fully human monoclonal antibodiy (mAb) against COVID-19 developed by a research team at the Institute of Microbiology of the Chinese Academy of Sciences (IMCAS).
An online AI diagnosis system for COVID-19, has been implemented recently in China Science & Technology Cloud of Chinese Academy of Sciences (CAS), offering free online diagnosis service for COVID-19 to the world. According to the real test results in domestic hospitals, it takes 6~15 seconds to upload an adult's lung CT image data (30-50 levels), and takes only 10~20 seconds for AI diagnosis.
52 Sanlihe Rd., Xicheng District,
Beijing, China (100864)